#None #Securities Class Action #Faruqi & Faruqi #Vistagen

Vital Deadline for Vistagen Investors

Investors in Vistagen Therapeutics, Inc. (NASDAQ: VTGN) are urged to pay attention to an important deadline approaching on March 16, 2026. The legal firm Faruqi & Faruqi, LLP is currently investigating potential claims against the firm and highlights this urgent situation for investors who may have sustained losses. If you acquired shares during the designated Class Period, you should familiarize yourself with your rights and options for recourse.

Background on the Class Action

Vistagen has faced scrutiny after its executives allegedly provided misleading statements regarding the efficacy of its drug, fasedienol, particularly related to its trials for treating social anxiety disorder (SAD). The complaints allege that these statements contributed to artificially inflated stock prices, leading to significant losses for investors when the truth came to light.

On December 17, 2025, Vistagen reported disappointing results from its PALISADE-3 trial, revealing that the drug did not meet its primary efficacy endpoint. Following this announcement, the company’s stock plummeted by more than 81%, closing at just $0.88 per share. This sharp decline has left many investors questioning their stake in the company and seeking legal redress.

The Role of Lead Plaintiff

In a federal securities class action, the position of lead plaintiff is essential. The lead plaintiff is often the investor with the most significant financial stake in the case, who oversees the litigation process on behalf of the class. Investors who wish to be considered for this role must act before the impending deadline of March 16, 2026. Those who prefer not to take an active role can still remain part of the class without affecting their eligibility for any recovery.

Faruqi & Faruqi, LLP is encouraging anyone who suffered losses due to Vistagen’s alleged misconduct to contact them directly, including whistleblowers and former employees who may possess vital information regarding the company's actions.

How to Participate

Investors wishing to learn more about their legal rights or to discuss their options can contact Faruqi & Faruqi partner Josh Wilson at 877-247-4292 or 212-983-9330 (Ext. 1310). More information can also be found at their dedicated website for Vistagen’s case.

It's crucial for affected investors to act swiftly, especially with the deadline looming. Awareness and preparedness could play a key role in the outcome of the ongoing litigation.

Conclusion

With the March 16, 2026, deadline approaching, Vistagen Therapeutics investors must stay informed about the developments surrounding this significant securities class action lawsuit. Taking proactive measures by reaching out to legal experts could provide vital guidance in navigating this challenging landscape. This represents a pivotal moment for investors seeking justice and recovery from their losses related to Vistagen's stock.

This urgent alert serves as a call to action for those impacted – don't miss your opportunity to take part in the class action and protect your financial interests.